Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2022

Antifungal Activity of Human Cathelicidin LL-37, a Membrane Disrupting Peptide, by Triggering Oxidative Stress and Cell Cycle Arrest in Candida auris.

Journal of fungi (Basel, Switzerland) · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2022

The Selenoprotein Glutathione Peroxidase 4: From Molecular Mechanisms to Novel Therapeutic Opportunities

Biomedicines · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2022

MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.

International journal of molecular sciences · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2022

The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease.

International journal of molecular sciences · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2022

Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells.

Stem cell research & therapy · 2022

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2021

Glutathione in the Brain

International journal of molecular sciences · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2021

Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.

Frontiers in immunology · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2021

The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans

International journal of molecular sciences · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2021

Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.

Antibiotics (Basel, Switzerland) · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2021

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.

Open forum infectious diseases · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2021

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

Antibiotics (Basel, Switzerland) · 2021

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2021

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.

Nature communications · 2021

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.